financetom
Business
financetom
/
Business
/
Coterra Energy beats Q1 profit estimate, raises 2024 oil production outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Coterra Energy beats Q1 profit estimate, raises 2024 oil production outlook
May 2, 2024 1:53 PM

May 2 (Reuters) - Coterra Energy ( CTRA ) beat estimates

for first-quarter profit on Thursday as higher output volumes

helped U.S. shale producer counter a steep decline in natural

gas prices.

Coterra said it was increasing its 2024 oil production

outlook to 107,000 bopd from 102,000 bopd, up 2.5% at the

mid-point of prior expectation, driven by strong well

performance and faster cycle time.

Cottera Energy shares were up 2.2% in trading after the

bell.

Its total production stood at 686,100 barrels of oil

equivalent per day (boepd) in the January-March quarter, 8%

higher than last year.

For the current quarter, production is expected to be

between 625,0000 boepd and 655,000 boepd.

However, sales prices, without hedges, for natural gas in

the reported period declined nearly 40% to $2.00 per thousand

cubic feet (mcf).

Henry Hub futures, the benchmark for U.S. gas, have

traded below $2 per million British thermal unit (mmBtu) and

during the first three months of the year dropped to a

3-1/2-year low on warm winter weather and oversupply.

While crude prices were largely flat against last

year at $76 a barrel in the quarter, they remained at a

profitable level for oil and gas drilling.

"Coterra continues to fire on all cylinders, and shifting

our near-term capital program to focus on oil and liquids-rich

plays remains prudent. However, the company maintains

optionality to take advantage of a structural change in the

natural gas macro as LNG exports grow and electricity demand

increases," said Tom Jorden, CEO of Coterra.

The company reported adjusted net income of 51 cents per

share for the three months ended March 31, topping average

analysts' estimate of 41 cents per share, according to LSEG

data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Completes Acquisition of Alcyone Therapeutics
Biogen Completes Acquisition of Alcyone Therapeutics
Nov 14, 2025
04:24 PM EST, 11/14/2025 (MT Newswires) -- Biogen (BIIB) on Friday said it completed its acquisition of Alcyone Therapeutics, adding the company's ThecaFlex DRx implantable intrathecal delivery system to support future use with Spinraza, its spinal muscular atrophy treatment. The device is designed to replace repeat lumbar punctures and is currently being studied in the PIERRE trials. Biogen said it...
 Kitchen and Bath products supplier FGI Industries Q3 revenue misses estimates on tariff impact
 Kitchen and Bath products supplier FGI Industries Q3 revenue misses estimates on tariff impact
Nov 14, 2025
Overview * FGI Industries ( FGI ) Q3 revenue declines 0.7% y/y, missing analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting strategic growth investments * Gross profit increases 2% y/y, driven by strategic pricing and cost management Outlook * Company reiterates fiscal 2025 revenue guidance of $135 mln-145 mln * FGI sees strategic investments driving future revenue growth...
Venu Holding Q3 Loss Widens, Revenue Falls
Venu Holding Q3 Loss Widens, Revenue Falls
Nov 14, 2025
04:25 PM EST, 11/14/2025 (MT Newswires) -- Venu Holding ( VENU ) reported a Q3 loss of $0.15 per diluted share, widening from a loss of $0.13 a year earlier. Two analysts polled by FactSet expected a loss of $0.25. Revenue for the three months ended Sept. 30 was $5.4 million, down from $5.5 million a year earlier. Two analysts...
Ensysce Biosciences reports Q3 net loss
Ensysce Biosciences reports Q3 net loss
Nov 14, 2025
Overview * Ensysce reports Q3 net loss of $3.7 mln, driven by increased R&D expenses * Company initiates Phase 3 study of PF614, marking a major milestone * Ensysce completes $4 mln preferred stock financing to support development Result Drivers * Cash and cash equivalents were $1.7 million as of September 30, 2025, compared to $3.5 million as of December...
Copyright 2023-2026 - www.financetom.com All Rights Reserved